Authors

Yazmin Odia, Miami Cancer InstituteFollow
Bruno Bastos, Miami Cancer InstituteFollow

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors

Publication Date

2021

Content Type

Article

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

Citation

Journal of Clinical Oncology (2021) 39(15_suppl):2051-2051